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The chemical synthesis and metabolic characteristics 
of the lanosterol  analogue, 15a-fluorolanost-7-en-3~- 
01, are described. The  l5a-~uorosterol is shown to be 
a competitive inhibitor of the lanosterol l4a-methyl 
demethylase (Kt = 315 PM), as well as substrate  for  the 
demethylase enzyme. Metabolic studies show that  the 
15a-fluorosterol is converted  to  the  corresponding 
l6a-fluoro-3~-hydroxylanost-7-en-3~-a~dehyde by 
hepatic microsomal lanosterol  14a-methyl demethyl- 
me but  that  further metabolic conversion to cholesterol 
biosynthetic  intermediates is blocked by  virtue of the 
16a-fluoro substitution. When cultured cells are 
treated  with  the  fluorinated  lanosterol analogue, a de- 
crease  in 3-hydroxy-3-methylglutaryl (HMG)-CoA re- 
ductase  activity  and  immunoreactive  protein  was ob- 
served. However, when the lanosterol  14a-methyl de- 
methyla~-de~cient  mutant  cell  line,  ARM, is treated 
with  the  fluorosterol, no effect upon HMG-CoA reduc- 
tase is observed. Thus, metabolic conversion of the 
sterol  to  its  32-carboxaldehyde  analogue by the lanos- 
terol 14a-methyl demethylase is required for HMG- 
CoA reductase suppressor activity. Measurement of 
HMG-CoA reductase mRNA levels in 15a-fluorosterol- 
treated Chinese hamster  ovary (CHO) cells  reveals  that 
mRNA levels are not decreased by the  sterol as would 
be expected for a sterol  regulator of  HMG-CoA reduc- 
tase activity. The decrease in  ~MG-GOA reductase  pro- 
tein is due to inhibition of enzyme  synthesis,  suggesting 
that  the  lba-fluorosterol reduces  the  translational ef- 
ficiency of the reductase mRNA. Measurements of the 
half-life of  HMG-CoA reductase show that,  in  contrast 
to other  oxysterols, the ~~~-f luorolanostenol  does not 
increase  the rate of degradation of the enzyme. Col- 
lectively, these data support the premise that oxy- 
lanosterols  regulate HMG-CoA reductase  expression 
through a post-transcriptional process which may be 
distinct  from  other previously described sterol regu- 
latory mechanisms. 
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ductase (EC 1.1J.34) is the rate-limiting enzyme  governing 
cholesterol biosynthesis and  the synthesis of other isoprenoids 
in mammalian cells (I). It has been  suggested that regulation 
of this  important enzyme in cellular metabolism i s  under the 
control of a multivalent feedback  process  which  involves both 
end product sterol, as well as other non-steroidal mevalonate- 
derived products ( 2 ) .  Results to date demonstrate that sterol- 
dependent regulation of reductase activity i s  due primarily to 
a transcriptional control process which affects the level of 
reductase mRNA (3,4), although less dramatic post-transcrip- 
tional control by sterols has been  observed (5). Conversely, 
the non-steroidal regulation of reductase has been  shown to 
involve post-transcriptional mechanisms which entail en- 
hanced enzyme degradation and decreased translational eff- 
eiency of reductase message (6, 7). Thus, the differences 
between the two control processes are highlighted  in terms of 
mechanism as well as affector molecule. 
Recently there has been renewed interest as to whether 
cholesterol or some oxysterol precursor or product of choles- 
terol metabolism is responsible for the observed steroidal 
regulation of HMG-CoA reductase activity, Generation of 
regulatory oxysterols by means of a side pathway through 
epoxycholesterol has been  proposed as  an alternative to cho- 
lesterol as  the natural regulator of reductase activity (8-11). 
Similarly, oxysterol intermediates generated along the normal 
pathway of cholesterol biosynthesis have  been  shown to mod- 
ulate the reductase in a manner consistent with their involve- 
ment  in  the regulatory process (12, 13). In  the  latter case, it 
has been demonstrated that 3~-hydroxylanost-S-en-32-a1 
which arises during the course of lanosterol 14a-methyl de- 
methylation can  serve to regulate HMG-CoA reductase activ- 
ity when carbon flux through the sterol pathway is abnormally 
high (13). Mechanistic studies have also demonstrated that 
accumulation of 3~-hydroxy~anost-S-en-32-a1 is  favored  over 
demethylated end product under conditions when lanosterol 
substrate concentrations are saturating (14-16), thus sup- 
porting the cellular obse~ations on metabolic formation with 
kinetic data. Similarly, it  has been  suggested that  the level of 
this same or comparable intermediate may decrease under 
conditions when substrate pools  favor carbon flow to choles- 
terol (17). Collective~y, these observations support the notion 
that accumulation o~3~-hydroxylanost-S-en-32-al in situ may 
be the result of a designed integrated regulatory process which 
serves to control endogenous cholesterol biosynthesis under 
normal physiological fluxes of carbon flow-through the sterol 
pathway. 
The importance of the 3~-hydroxylanost-S-en-32-~ in the 
regulation of HMG-CoA reductase and a detailed understand- 
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ing of its mechanism have  been hampered, however, by inad- 
equate experimental systems which allow one to monitor 
specific effects of the endogenously generated sterol metabo- 
lite. One approach which we have taken to solve this dilemma 
has been through the generation of cholesterol biosynthetic 
mutants which  allow dissection of the process  genetically (18). 
A second and equally important approach is to use synthetic 
substrates. The latter approach has suffered in the past, 
however, from the  inherent problem that synthetic metabo- 
lites  are ultimately converted to cholesterol as a consequence 
of normal metabolism. To circumvent this problem, we have 
designed and synthesized a lanosterol analogue which can 
only  undergo limited metabolism by the lanosterol 14a-methyl 
demethylase of the cholesterol biosynthetic pathway, The 
compound described, l5a-fluorolanost-7-en-3~-ol, by virtue 
of its 15a-fluor0 substitution, is incapable of undergoing a 
complete demethylation cycle and subsequent conversion to 
cholesterol (19,201 (Scheme I). This inability to be converted 
to cholesterol makes the 15a-fluorolanosterol an ideal agent 
to study the regulatory properties and mechanism of oxylan- 
osterol formation and control of HMG-CoA reductase activity 
in cultured cells. 
In this report, we describe the metabolic characteristics of 
the 15a-fluorolanostenol and conditions where the fluorinated 
sterol is  metabolized to  its aldehyde analogue. Additionally, 
we demonstrate that the 15a-fluorosterol is an active sup- 
pressor of HMG-CoA reductase activity in wild-type, but  not 
~anosterol l ~ ~ - m e t h y l   d e m e t h y l ~ e  defici nt, CHO  cells. Most 
i~ t e re s t~~g ly ,  the regulat~o~ of HMG-CoA reductase by the 
fluorinated lanostenol in cell culture experiments is shown to 
be due to a post-transcriptional process analogous to non- 
steroidal reductase regulators and  not  transcriptional control 
as would  be expected for a sterol. These results demonstrate 
that cholesterol precursor sterols regulate HMG-CoA reduc- 
tase and cholesterol biosynthesis by a mechanism distinct 
from that of cholesterol and oxycholesterol ~ e ~ b o ~ i t e s .  These
findings bring into question the identity of the putative HMG- 
CoA reductase non-steroidal regulator which functions as a 
post-transcriptional modulator of reductase expression. 
EXPERIM~NTAL PROCEDURES 
~e~~ 
~ a ~ o s t e r o ~  ~4n-Methyl D e ~ e ~ ~ ~ ~ a s e  Assay-Lanosterol 24n- 
methyl demethylase was assayed as described previously (16). Kinetic 
SCHEME I. 16a-FluoroIanost-7-en- 
3@-01 metabolism as catalyzed by the 
lanosterol 14a-methyl demethylase. 
Metabolism of the 15n-fluorolanostero1 
proceeds through aldehyde formation. 
Further metabolism of the lanostenol re- 
quires 15ol-proton loss which is pre- 
vented by the 15a-flUOrO substitution. 
analyses required the following assay m ~ ~ c a t i o n .  Toluene stock 
solutions  containing 1 pCi of ~24,25-'W]24,25-dihy~o~anost"8-en-3fl~ 
01 substrate, 41.7-250 nmol, in addition to 0,50, or 100 nmol  of 15a- 
fluorolanost-7-en-3fl-ol for  each  substrate  concentration, were evap- 
orated in the bottom of each assay tube under Nz to remove all 
toluene. To each tube 5.0 mg  of Triton WR1339  was added in acetone 
to dissolve the sterols and  then once again dried under Nz to form a 
detergent-sterol film in  the bottom of the tube. Dimethyl sulfoxide, 
50 pl, was added to each tube and vortex-mixed to suspend the 
detergent-sterol matrix followed by additions of 25 pl of 1.0 mM 
AY9944 (in a 10% propylene glycol) and 10 pl of 25 pM sodium 
cyanide. Two mg of rat liver microsomes prepared from male Spraque- 
Dawley rats  that were fed a 3% cholestyramine diet (16) were added 
to each  tube in 390 &I of a I00 mM KxP04,  pH 7.4,O.l mM EDTA, 
0.1 EIM dithiothreitol, 20% glycerol buffer. The microsomes and 
contents listed above were ~ u i l i b r a ~ d   a t  37 "C for 5 min and  the 
assay initiated  with  25 pl of a 20 mM NADPH/isoc~trate dehydrogen- 
ase generator mix (16). All other aspects of stopping the assay, 
saponification, extractions, and analysis by reverse-phase WPLC were 
as described (16). 
Metabolism of 125 nmol of lanost-7-en-3P-01 or  15a-fluorolanost- 
7-en-30-01  were performed under the same conditions as described 
above with the exception that 24,25-dihydroIanosterol was omitted. 
The extracted nonsaponi~abie sterols were split in equal portions 
and derivatized by the two schemes listed below and analyzed by GC/ 
MS. 
Deriuatization of Sterols for GC/MS Analysis-The C32-oxysterol 
products of lanost-7-ene-38-01 and Ea-fluorolanost-7-ene-30-01 are 
unstable during GC/MS analysis, since they decompose to their 
respective A8(24) unsaturated sterol under the high temperature 
cond~tions employed during  analysis (21). Therefore, separate  pro- 
cedures are described for characterizing the 3&32-dioi sterols versus 
the 3~-hydroxy-32-aldehyde  sterols by GC/MS. The first procedure 
requires that 3~-hydroxy-32-aldehyde sterols be reduced to a 32- 
hydroxy group prior to derivation. The sterol sample was dissolved 
in 500 p1 of methanol at room temperature, and 5.0 mg of NaBH, 
was added and allowed to react for 3 h. Water, 2 ml,  was then added 
to quench the reaction, and  the sterols were extracted with 10 ml of 
petroleum  ether. The petroleum ether extract was evaporated under 
Ns gas and the reduced sterols subsequently derivatized to their 
respective trimethylsilyl ethers. The reduced sterols were dissolved 
in 200 p1 of dry pyridine and 200 btl of "Tri-Si1 TBT" reagent (Pierce 
Chemical Co.), capped under N2 gas, and reacted overnight at 80 "C. 
The  TMS reaction mix was then dissolved in 10 ml of petroleum 
ether  and backwashed with 2 ml of 10% solution of sodium bicarhon- 
ate. The organic phase was removed and evaporated to dryness under 
Nz. The final  sterol  product was dissolved in 250  a1 of toluene, and 
4.0-pl aliquots were analyzed by GC/MS as described beiow. 
The  alternate method for derivatizing 3@,32-&01 sterols as well as 
their respective substrates  and demethylated products was accom- 
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plished by performing the "Tri-Si1 TBT" reaction as described here 
without NaBH. reduction. As above, the final derivative was dissolved 
in 250 pl of toluene and 4.0 p1 was analyzed by GC/MS. 
GC/MS Analysis of Sterols-Derivatized sterols were analyzed by 
GC/MS employing a  Hewlett-Packard 5890 gas chromatograph 
equipped with 5970 mass selective detector  (14). A capillary column 
of  DB17-30W (J & W Scientific, Inc.) was used for sterol  separations 
with helium carrier gas and the following temperature program: 
starting temperature, 235 "C; ramp  rate,  5 'C/min; final temperature, 
265 "C. Total ion chromatograms were run in the ion range of  50-800 
atomic mass units. 
Cell Culture-CHO cells were cultured in McCoy's 5A medium 
(modified) supplemented with 1% Cab-0-Si1 (Kodak) delipidated 
fetal bovine serum (DLSP)  as described previously (13). Cells were 
seeded at a density of  0.3 X lo6 in 60 X 15-mm tissue culture dishes 
(Costar) in 4 ml of the above medium 48 h prior to  the  start of each 
experiment (13). 
AR45 cells, a CHO  cell mutant deficient in lanosterol demethylase, 
were cultured in McCoy's  5A medium (modified) supplemented with 
2.5% fetal bovine serum as described (18). Cells were washed twice 
with Hanks' balanced salt solution (GIBCO) before replacing the 
medium with 4 ml of McCoy's 5A medium (modified), 1% DLSP, 18 
h  prior to  the  start of experiment. 
Determinatwn of HMG-CoA Reductase Activity, Immunoreactive 
Protein, and Quuntitation of mRNA Levels in Sterol-treated CHO 
Cells-HMG-CoA reductase activity and immunoreactive protein 
measurements were performed on cell homogenates exactly as de- 
scribed previously in  detail (13) or on permeabilized cell cultures as 
reported by Leonard and Chen (22). Immunoblots were quantitated 
by scanning with an LKB UltroScan L densitometer. 
HMG-CoA reductase mRNA levels were quantified by Northern 
blot analyses of poly(A+) RNA. For  these  determinations, cells were 
seeded in 150-mm tissue culture dishes (Costar) at 0.9 X 106/dish in 
20  ml of McCoy's 5A (modified) medium containing 1% DLSP. Cells 
were  allowed to grow for up to 5 days at  37 "C in 5% C02.  On the day 
of treatment,  the medium was replaced with fresh medium, and cells 
were treated with sterols suspended in 2.5% bovine serum albumin 
in 5% ethanol such that the final ethanol concentration did not 
exceed 0.5% (v/v). All treatments were done in triplicate. The  treat- 
ment was continued for 16 h at which time cells were harvested by 
first removing culture medium and washing with 3 X 10 ml of cold 
(4 "C) 50 PM Tris-HC1, 155 pM NaCl, pH 7.4 (Tris/NaCl buffer). A 
small portion (14 cm') of each culture which was removed by scraping 
into 0.7 mf of Tris/NaCl buffer for activity  measurements and im- 
munoblots. Total RNA  was isolated from the remainder of the cul- 
tures by guanidine isothiocyanate extraction and CsCl gradient 
centrifugation, with further  fractionation by oligo(dT)-cellulose chro- 
matography (23). Poly(A+) RNA (2.5 pg) quantitated spectrophoto- 
metrically was electrophoresed in 0.66 M formaldehyde, 1% agarose 
gels (23). Following transfer  to nitrocellulose filters, hybridizations 
were performed with the following nick-translated [ C X - ~ ~ P J ~ A T P -  
labeled cDNA probes (23): the BamHI insert of the HMG-CoA 
reductase plasmid pRed227 (obtained from ATCC); the  PstI insert of 
the @-actin cDNA (24); and the PstI insert of the gluteraldehyde 
phosphate dehydrogenase plasmid. pGAPDH plasmid (a kind gift 
from K. Hastings and C. P. Emerson, Jr. to P. Benfield, Du Pont) 
(25). The  latter two probes were  used as  internal  standards  to  quan- 
titate mRNA  recovery. Autoradiography at  -70" for 3-24 h was used 
to detect the location of radioactivity on filters, and mRNA quanti- 
tation was done by cutting individual bands from the filter and 
counting in a liquid scintillation counter. Similar results were ob- 
tained by densitometric scanning of autoradiograms. 
HMG-CoA Reductase Synthesis and Degradation-Exponentially 
growing cells were labeled in medium containing [35S]methionine (40 
pCi/ml, 40 Ci/mmol). For synthesis measurements, cells were pulsed- 
labeled with [36S]methionine for 30 min at various times  after treat- 
ment with sterols. For degradation measurements, untreated cells 
were labeled for 2 h with [35S]methionine and  then cell monolayers 
were rinsed twice and incubated in medium containing 10 mM unla- 
beled L-methionine with or without oxylanosterol. Cells were har- 
vested in Tris/NaCl and frozen at  -80 "C. HMG-CoA reductase was 
immunoprecipitated essentially as described by Tanaka et al. (5). 
HMG-CoA reductase was immunoprecipitated with polyclonal anti- 
reductase igG. immunoprecipitates were solubilized at  37 "C in  SDS- 
urea sample buffer and analyzed by electrophoresis on SDS, 10% 
polyacrylamide slab gels [35S]methionine-labeled proteins were visu- 
alized by fluorography using EN3HANCE (Du Pont-New England 
Nuclear). Radiolabeled HMG-CoA reductase was quantitated by cut- 
ting the appropriate band from the gel, solubilizing the slice with 
Protosol (Du Pont-New England Nuclear), and counting in a liquid 
scintillation spectrophotometer. Background radioactivity was deter- 
mined with preimmune rabbit serum. The half-life of HMG-CoA 
reductase was calculated from the slope of a semi-log plot of disinte- 
grations/min  in reductase versus time of chase. 
Protein Determinations-Protein was determined by the Bio-Rad 
dye binding assay according to  the manufacturer's directions employ- 
ing bovine serum albumin as  a  standard. 
Materials 
Preparation of ~~-Benzoyloxy-~5a-f l~orolanost-7-ene (2f"The 
starting material (see Scheme 11) used to prepare the desired 15a- 
fluorolanost"i'-en-3~-01 was the previously reported 3P-benzoyloxy- 
lanost-7-en-15a-01 (26-29). Diethylamino sulfur trifluoride (5.75 ml, 
46 mmol) was added to a solution of 3~-benzoyloxylanost-7-en-15a- 
01 (1, 1.6 g, 2.92 mmol) in dry (distilled from phosphorus pentoxide) 
dichloromethane (100 ml) (30) under argon at -78". The reaction 
was stirred at  -78 "C for 0.5 h, then diluted with dichloromethane 
(100 ml). Aqueous sodium bicarbonate was added until the aqueous 
phase was neutral, and  the mixture was extracted with to1uene:ethyl 
acetate, 1:1 (3 x 100 ml). The combined organic solutions were dried 
over anhydrous magnesium sulfate, filtered, and solvents removed in 
vacuo to give  1.7 g of a complex mixture. 
Purification by chromatography on silica gel (eluant 5% ethyl 
acetate in hexane), followed by HPLC on silica gel (eluant 25% 
toluene in  hexane), yielded 294  mg (18% yield) of 3P-benzoyloxy-15a- 
fluorolanost-7-ene (2). 
Physical data (2): [.Iz5 = +45.9 t- 2.0" (c = 1.06, CHCI,); m.p. = 
226-227 "C (powder); RF = 0.50 (5% ethyl acetate in hexane); 0.15 
(25% toluene in hexane); NMR (300 MHz, CDCM:  8.06 (d, J = 7.4 
Hz, 2H, phenyl), 7.55 (m, IH, phenyl), 7.45 (m, 2H, phenyl), 5.51 (m, 
= 9.4,  5.6 HZ, IH, 3-CHO), 2.18-1.27 (m,  23H), 1.15 (s, 3H, 31-CH3), 
0.87 (unresolved d, 9H, 21, 26, 27-CH3), 0.70 (s, 3H, 18-CH3); IR 
(KBr, cm"):  2960 (m), 2930 (m, CH saturated), 1705 (s, C=O), 1460 
(m), 1450 (m), 1390 (m), 1380 (m), 1365 (m), 1280 (s, C-01, 1120 
(m, C-F), 1035 (m), 1025 (m);  MS  (EI): 550 (20% M+), 413 (loo%, 
M-C8HsO2); high resolution mass spectroscopy for C3,Ha5O2F (M+): 
calculated 550.4186, found 550.4163. 
Preparation of lScu-Muorolanost-7-en-3~-01 (3)"Lithium alumi- 
num hydride (290 mg, 7.6 mmol) was added slowly to a solution of 
3~-benzoyloxy-15a-fluorolanost-7-ene (2294 mg,  0.534 mmol) in die- 
thyl  ether (40 ml) and tetrahydrofuran  (10 ml) a t  0 "C under nitrogen. 
The reaction was stirred for 10 min, then quenched with the addition 
of sodium sulfate decahydrate (1 9). The mixture was diluted with 
diethyl ether (50 ml) followed by ethyl acetate (20 ml). The resultant 
solution was filtered though a  sintered glass funnel and the solvents 
removed in vacuo. The resulting solid was crystallized from isopro- 
panol to give  230  mg (96% yield) of 15a-fluorolanost-7-en-3P-ol (3). 
The crystals had a m.p. = 159-160 "C, and the NMR showed co- 
crystallization with isopropanol (2:1, 3:isopropanol). The crystals 
were then dissolved in benzene and  the solvent removed to give an 
amorphous solid. 
Physical Data (3): [a]25 = +24.6 4.0" ( c  = 0.5, CHC1,); m.p. = 
172.5-173  "C (powder); RF = 0.18  (1:2:7, ethyl acetate:toluene: 
hexane); NMR (300 MHz, CDC13):  5.50 (m, lH, 7-CH), 5.05 (ddd, J 
CHO), 2.18-1.27 (m, 23H), 1.10 (d, J = 3.6 Hz, 32-CH3), 1.01 (9, 'H, 
CH,), 0.92-0.87 (m, 12H, methyls), 0.71 (s, 3H, 18-CH3); "F NMR 
(CHC13, cm": 3620 (w, OH), 2960 (s), 2870 (m, CH sat), 1467 (m), 
1448 (m), 1384 (m), 1367 (m), 1090 (w, CF), 1028 (m), 995 (m), 670 
(m); MS (EI): 446 (65%,  M+), 431 (40%, M+ - CHJ, 413 (50%, M+ 
- CH3, - H20), 306 (loo%, M+ - CgH160); high resolution mass 
spectroscopy for C30H,10F (M+): calculated 446,3924, found 446.3917; 
EA for C30H610F: calculated, C 80.66%, H 11.51%, F 4.25%; found, C 
80.83%, H 11.29%, F 4.11%. 
Synthesis of lanost-7-en-3P-01 used in these studies was performed 
as described by Woodward et al. (26). 
Other Materials-A11 reagents used for lanosterol 14a-methyl de- 
methylase and HMG-CoA reductase activity determinations were as 
described previously (13, 16). ~-['~S]Methionine (1120 Ci/mmol was 
from Du Pont-New England Nuclear. Guanidine isothiocyanate, 
CsCl, and oligo(dT)-cellulose Type  2 and Type 3 were  from  GIBCO. 
Agarose  was  from Bio-Rad. Nitrocellulose was obtained from 
IH,  7-CH), 5.05 (ddd, J = 56.6, 9.2,5.6 HZ,  lH,  15-CHF),4.78 (dd, J 
1.10 (d, J =  3.6 HZ, 3H, 32-CH3), 0.95 ( s ,  3H, CH3),  0.94 (9, 3H, CH3), 
= 56.6,  9.2,  5.6 HZ, lH,  ISP-CHF), 3.27 (dd, J = 10.6,  4.9 HZ,  IH, 3- 
(188.2 MHz, CDC13):  -192.9 (ddq, J = 56.6,  27.5, 3.6 HZ 15-CHF); IR 
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SCHEME 11. Synthetic route to 15a- 
~uorolanost-7-en-3&01. Structures 
shown refer to those given in the text 
and  identified by  boided  numerals. 
Schie~cher and  Schuell,  and  x-ray film was  from  Kodak.  Anti-HMG- 
CoA reductase IgG was a generous  gift of Dr. Gene Ness,  University 
of Southern  Florida. All other  reagents  were  the  best  grade  commer- 
cially available. 
RESULTS 
C ~ r ~ t e r ~ z u t ~ n  of J5a-Fluorolanost- 7-en-3~-ol-The  15a- 
fluor0 stereochemica~ assignment was critical for further stud- 
ies with the l5a-ffuorolanosteno~ in our enzymic and cell 
biolog~ca~ studies. This assignment was based upon NMR 
studies. The ffuorine-pro~n coupling constant of 3.6 Hz 
which we observed  between the C32-methyl and the ffuorine 
groups is consistent with the cis orientation as shown in 
Scheme I (31). However, these data alone were insuffic~ent 
for proper stereochemica~ assignment, A d ~ t i o n a ~  evidence 
was  also  provided by a series of nuclear  Overhauser effect 
(NOE) studies. Previous NOE experiments conducted on 3p- 
benzoyIoxytanost-7-en-l5icr-oi (27) gave an NOE between the 
15s-hydrogen and the C18-methyl group.  Conversely, the 38- 
benzoyloxylanost-7-en-15fi-ol provided an observed NOE be- 
tween the 15a-hydrogen and  the 32 methyl. in  the case of the 
only  observed ffuorinated steroid from the ~e thy~amino  sulfur 
triffuoride reaction, we observe an NOE between the 15- 
~ y ~ o g e n  and the  18-methy~ group,  By  analogy to  the above 
cited experimen~, these NOE results, along  with the ffuorine- 
proton coupling cons tan^, allowed us to a s s i ~ e d  the fluori- 
nated steroid s t ~ c t u r e  as the desired 3~-benzoyIoxy-l5a- 
ffuorolanost~7-ene (2). 
Metabolic C ~ r ~ c t e r i s t ~ ~  of I~a~F~~rolanost-7-en-38-nE 
with Hepntic Microsomes-Once proper stereochemical as- 
signments had been  made, our initial studies with the 15a- 
fluorosterol were designed to assess its metabolic behavior 
with hepatic microsomes. Previously, WE have shown that 
lanostenols with a A7 double  bond are poorly  metabolized by 
the lanosterol demethylase despite having  reasonable affiiity 
for the enzyme  (32). This poor  metabolic ~harac~r i s t ic  cou- 
pled  with the inherent ~fficulty in  detect~ng oxylanosteno~s 
made formation and de~ct ion  of the 15a-ffuoro-3P-hydroxy- 
lanost~7-en-32-aldehyde a difficult task. Our efforts, there- 
fore,  did not focus  upon detailed kinetics of formation, but 
rather upon simple demonstration of formation with more 
extensive characterization of the 15a-~uorolanos~roI by in- 
hibition kinetics toward the lanosterol 14a-methyl demeth- 
ylase. 
Shown in Fig. 1 is the GC/MS chromatogram of reaction 
products generated during incubation of 15a-ffuoroianost-7- 
en-3fi-01 with hepatic microsomes. The peak corresponding to 
1 
J 
3 x 105 t 
I 
10 15 20 25 
TIME ( m i n ~ t ~ s )  
FIG. 1. GC/MS chromatogr~  of reaction products of 150r- 
fluorolanost-7-en-3fl-ol with hepatic microsomes. The 1501- 
fluoroianostenol (250 p ~ )  was incubated with hepatic microsomes 
(2.0 mg) for 1 h at 37 “C, at which  time  the  assay  was  stopped  by  the 
addition  of 15% KOH in 95% methanol.  Following  saponification  and 
extraction, sterols were prepared for GC/MS  analysis by reduction 
and TMS derivatization as detailed under “Methods,” Chromato- 
graphic  peaks  identified by retention  time  are:  TMS-cholesterol, 11.5 
min;  choiesterol, 14.8 min; diTMS-l5~-fluorolanost-7-en-3~,32-diol, 
15.7 min;  and T~S-15~-fluoro~anost-7-en-3~-01, 13.0 min. 
a retention time of 15.7 min rep re sen^ the derivatized 15a- 
~uoro~anostenol-32-aldehyde obtained through metabo~ism of 
the parent substrate seen at a retention time of  19.0 min. No 
metabolite was seen  when incubations were done anaerobi- 
cally or in the absence of NADPH (data not shown). As 
mentioned above, the lability of oxy~anostenols to  the gas 
chromatographic conditions employed during analysis re- 
quired extensive derivatization prior to   GCmS identification 
(see ‘‘Methods”). Thus, the following fragmentation ions were 
observed in  the mass spectrum of the reduced  aldehyde TMS 
derivative: 571 (10%; M+ - F - CH3), 516 (12%; M‘ - 
HOTMS~, 484 (95%; M+ - F - CHZOTMS),  413 (20%; M* - 
H O T ~ S  .- C~ZOTMS~,  394(18%, M+ - CgH~~OTMS, 393 
(18%; M‘ - ~ O T ~ S  - CH~OTMS - HF)  and 379  (46%; M+ 
- CH3 - CgH~~OTMS~.  The absence of a m o ~ e c u ~ ~ r  ion of 
606 is  consistent with the reported behavior of the Ianosteno~ 
14ff-aIdehyde in this GC/MS system (21). The loss of HF and 
F in the metabolite spectrum are also consistent with the 
same type Iosses in the  parent structure which shows: 518 
(26%; M‘), 428 (30%; M” - HOTMS), 413 (88%; M+ - 
(10%; M” - HF - HOTMS - CH3). GC/MS analysis of 
reaction mixtures which  were not reduced prior to derivati- 
H O T ”  - C&), 394 (10%; M” - F HOTMS - CH3), 393 
zation revealed only modest amounts of d e t e c ~ b ~ e  14a-alco- 
hol (Table I). This finding indicates that  the Ilia-alcohol is 
present in the reaction mixture in much smaller amounts 
compared with the l~~-a ldehyde ,  again consistent with pre- 
vious metabolic studies employing ~hy~o lanos te ro l  (21). 
Evidence for me~bolism of the 15a-fluoroIanosterol to  the 
32-formyloxy interme~ate  was not obtained in  these studies. 
We a t t r i b u ~  this lack of a ~ ~ ~ t y  to generate the  formylox~ 
intermediate to  the inherent low rate of metabolism of the A7 
lanosterol series (32) and  the inability to generate the for- 
myloxy intermediate when using lanosterol as substrate due 
to  the kinetic properties of the 14a-demethylase enzyme (33). 
Further  eva~uation of the  l5a-~uorolanostenol  as a sub- 
strate fox the lanosterol 14a-methy~  demethy~ase was based 
upon inh~b~tion kinetics employing 24,25-~hy~olanosterol 
as substrate with a cell-free preparation of the demethylase 
enzyme. The double-reciprocal plot of demethylase activity in 
the presence of several conce~trations of the  15a-~uorolan- 
ost-7-en-3/3-01 is shown in Fig. 2. The  data clearly demonstrate 
that  the sterol is a competitive inhibitor of the demethylase 
with respect to dihydrolanosterol showing a IC, = 315 pM. 
These  data  are consistent with the observation that  the 15a- 
fluorosterol inhibits  the conversion of C30 sterols to C,, sterols 
in cultured CHO cells (50% inhibition at a concentration of 
5 PM in the culture medium, data not shown). Thus, the 
notion that  the 15~-~uoro~anos teno~ is a substrate for the 
lanosterol Ilia-methyl d~methylase is confirmed by kinetic 
studies as well as by metabolic convers~on. 
The Effect of ~ ~ a - F ~ ~ ~ ~ ~ ~ s t - 7 - e n - 3 / 3 - 0 1  upo  ~ ~ G ~ C o A  
~ e ~ ~ t ~ e  Actiuity in Chinese ~ u ~ t e r  Ova y Cetls-The next 
series of experiments with the fluorinated sterol were con- 
ducted in CHO cells. Our interest was in  the ability of the 
compotrnd to modulate ~ ~ G - C o A  reductase activity through 
an  oxys~rol-dependent mechanism. As shown in Fig. 3, the 
l5a-fluorol~nosterol shows a concentration-dependent sup- 
pression of ~ M G - C o A  reductase activity. This  is  a unique 
and specific property for the 15a-fluoro-substituted fanos- 
TABLE I 
GC/MS c ~ ~ ~ ~ e r i ~ u t ~ o n  of ~ ~ ~ ~ l i t ~ s  deriued from ~ ~ s t - ~ - e n ~ 3 B ~  
01 and lfin-fluorokmost-7-en-3~-ol ~~~~~d with ~ p u ~ i c  
~ ~ r o s o ~ ~ s  
I n c u ~ t i o n  of sterols with hepatic microsomes was performed under 
standard lanosterol demethy~ase conditions for 1 h with the following 
exceptions: 250 phrf sterol, 5.0 mg of Triton WR-1339, and 10% 
dimethyl suIfox~de. Nonsaponi~able sterols were extracted as de- 
scribed previousiy (16) and were split into two equal portions for 
derivatization and analysis by the schemes outiined  under "Methods." 
This ~ i f f e ~ n t i a 1  derivatization procedure allows for quantitation of 
both Ianosteroi 14~-aicohol  and 14n-aldehyde me~bolities, as well as 
demethylated diene sterol. 
Substrate Product Total sterol 
% 
Lano~t-7-en"3~-0~' 91.3 
~nost-7-ene-3~,32" 0.8 
3 ~ - ~ y ~ x y ~ ~ o s t * 7 -  4.9 
""". _ l _ - ~ - l _ _ _ l ~  
diol 
en-32-a1 
7,14-dien-3~-01 
~ , ~ - ~ i m e t h y ~ c h o l e s ~ ~  3.0 
15a-Fluoro-lanost-7-en- 97.1 
l5~-Fluoro- lanos t~~~ 0.6 
3 ~ - H y ~ o x y - l 5  a pha- 2.3 
38-olb 
ene-3@,32-&01 
ffuoro-lanost-7-en- 
32-a1 
Conversi~n rate = 0.09 nmol/min/mg. 
Conversion rate = 0.03 nmol/min/mg. 
-0.016 -0.008 0.000 0.008 
1 /st1 JUM) 
FIG. 2. Kinetics of 16tu-fluorolaoost-7-en-3B-ol i n h i ~ ~ t ~ o ~  
of lanosterol  14a-methyl  demethylase  activity. Lanosterol 14n- 
methyl demethylase was assayed using [2~,25-3~~J24,25-dihy~olan-  
osterol as  substrate in the absence (8) or presence of 100 pM (a) or 
200 pM (A) l5~-ffuoro~anost-7-en-3~-ol. sl pes of the reciprocal plots 
of the kinetic data were determined and plotted against inhibit~r 
concentration (inset) to determine the inhibition constant Ki = 315 
p ~ .  Values plotted are  the mean of duplicate determ~nations which 
varied by less than 5%. 
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FIG. 3. ~ u ~ ~ ~ ~ s i o n  of ~ ~ G - C o A  reductase activity in CHU 
cells treated with 16a-fluorolanost-7-en-3~-0~. Chinese ham- 
ster ovary cells were treated with increasing concentration of either 
l5n-~uorolanost-7-en-3~-oI r Ianost-7-en-3~-01 as described under 
"Methods." After 6-h exposure to  the sterol, cells where processed for 
HMG-CoA reductase activity determinations employing the ~ ~ t o n ~ n  
ceil permeabilization assay (22). Results represent the average of 
dupiicate determinations on replicate dishes. Clased circles, lanost-7- 
en-3B-ok closed ~ r i a ~ g ~ s ,  l5~-~uorolanost-7-en-3~~ol. Control 
(100%) activity = 479 pmol/min/mg. Standard  errors were less than 
5%. 
tenol, since lanost-7*en~~~-ol,  the n o n - f l u o r ~ n ~ ~ d  analogue, 
is without effect upon HMG-CoA reductase under identical 
conditions (Fig. 3) .  The nature of the suppression is consistent 
with an oxysterof-type ~ e c h a n ~ s m  since the decrease in 
~MG-CoA reductase activity is accompanied by a decrease in 
the  amount of immunoreactive reductase protein as shown in 
Fig. 4. Con~rmation  that  15~"fluorinated  lanosteno~ required 
metabolism by the lanosterol 14a-methyl demethylase to sup- 
press HMG-CoA reductase activity in these cell experiments 
was obtained through investigations employing the ~anostero~ 
14~-methy~  demethylase-de~cien~ m u t ~ t  AR45 (18). Treat- 
ment of AR45 cells with the ~uorinated sterol does not 
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FIG. 4. Immunoblot analysis of HMG-CoA reductase  protein 
in  sterol-treated cells. Chinese hamster ovary cells were treated 
with either lanost-7-en-3@-01 or 15cu-fluorolanost-7-en-3@-ol as de- 
scribed in the legend to Fig. 3. A and B,  cells were harvested by 
scraping into sonication buffer, sonicated, and cell pellets isolated by 
centrifugation. Cell pellets were suspended in SDS-polyacrylamide 
gel electrophoresis buffer and 10 pg  was loaded per well for separation 
and immunoblot analysis with anti-HMG-CoA reductase antibody. 
A ,  wild-type CHO cells. B, lanosterol 14a-methyl demethylase-defi- 
cient mutant, AR45, cells. C, immunoblots from CHO cells treated 
with 15a-fluorolanost-7-en-3~-ol were quantitated by scanning with 
a laser densitometer. The amount of immunoreactive protein is 
represented as the area  under the absorbency curve. The average and 
range of values from replicate dishes are shown. Parallel cultures 
were harvested for determination of HMG-CoA reductase activity  in 
cell sonicates as described under “Methods.” Data for enzyme activity 
represent the means and  standard errors of four samples. 0, enzyme 
activity; 0, immunoreactive protein. 
produce a decrease in  immunoreactive HMG-CoA reductase 
protein (Fig. 4B)  nor does it  inhibit reductase  activity  (control 
= 471 f 30 pmol/min/mg; sterol = 539 & 25 pmol/min/mg; n 
= 3). The lack of effect is not due to a  nonresponsiveness of 
the AR45 cells to oxysterols, since  suppression of HMG-CoA 
reductase is still observed when AR45 cells are  treated with 
25-hydroxycholesterol. Attempts  to isolate the metabolic 
product of the 150-fluorolanosterol from wild-type CHO  cul- 
tures have thus far been unsuccessful. 
Evidence for a Post-transcriptional Mechanism of HMG- 
CoA Reductase Regulation by l5a-Fl~rolan~st-7-en-3~-ol- 
To  further characterize the suppression of HMG-CoA reduc- 
tase caused by the 15a-fluorinated  sterol, we measured the 
amount of reductase mRNA in  treated  and nontreated CHO 
cells. It was anticipated  that  the primary effect of the  15a- 
fluorosterol would  be to change the level of reductase mRNA 
in a manner  consistent with  a transcriptional control process 
analogously to  other sterols (3, 4). The effect with the  15a- 
fluorolanostenol  upon  reductase mRNA, however,  was oppo- 
site  to  this exRectation. The results of a  representative exper- 
iment are shown in Fig. 5 and Table 11. Chinese hamster 
ovary cells treated with the compound actually showed an 
increase  in the  amount of reductase mRNA compared with 
controls. In four independent  experiments, the increase 
amounted  to a 2-fold induction in reductase mRNA over a 
16-h period. At the same  time that  the mRNA increase was 
observed, the level of reductase  protein and activity decreased 
to 16% of control levels (Table 111). This effect appears to be 
unique for the fluorinated  sterol since 25-hydroxycholesterol 
decreased the  amount of reductase mRNA, protein, and activ- 
ity in  agreement  with published results (3,4). 
To further characterize the effects of the  l5a-fluor0  ana- 
logue on HMG-CoA reductase gene expression, the rates of 
reductase synthesis  and degradation were measured. Synthe- 
sis of HMG-CoA reductase in CHO cells was measured by 
monitoring the incorporation of [35S]methionine into immu- 
noprecipitable protein  in the presence or absence of sterol. 
The results of a  representative  experiment are shown in Fig. 
6. Incubation of cells with the 15a-fluorolanostenol decreased 
the  rate of synthesis of reductase (Fig. 6B) in the absence of 
any affect on  total protein  synthesis as assayed by the incor- 
poration of [35S]methionine into acid-perceptible protein (Fig. 
6A). Table 111, which summarizes the results of four inde- 
pendent experiments, show that  the 15-fluorolanostenol in- 
hibits HMG-CoA reductase  synthesis  without  a corresponding 
decrease in mRNA levels. These observations suggest that in 
contrast  to  the  transcriptional regulation of HMG-CoA re- 
ductase  reported for other oxysterols, regulation by the 15- 
fluorolanostenol reduces the  translational efficiency of reduc- 
tase mRNA. 
The effects of 15a-fluorolanost-7-en-~-ol n the half-life of 
HMG-CoA reductase were determined and results from a 
representative  experiment are shown in Fig. 6C. Cells were 
C 250H 15a-F 
HMGR - 
GAPDH - @ 
I I  
FIG. 5. Autoradiogram of Northern  blot  analysis of poly(A+) 
RNA in sterol-treated CHO cells. Northern blot analysis of 
poly(A+) RNA was performed as described under “Methods.” Hybrid- 
izations were performed using nick-translated cDNA probes to HMG- 
CoA reductase (HMGR) and glutaraldehyde phosphate dehydrogen- 
ase (GAPDH). A representative autoradiogram is shown. C, ethanol 
control; 250H, 25-hydroxycholestero1(2.3 p ~ ) ;  15cu-F, l5a-fluorolan- 
ost-7-en-3@-01(5 p ~ ) .  
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TABLE I1 
Effect of 25-hydroxycholestero1 and 15a-fluorolnnost-7-en-3~-ol upon HMG-CoA reductase activity and mRNA levels in treated CHO cells 
CHO cells were treated with 25-hydroxycholestero1 or  the 15a-fluorolanosterol at 2.5 p~ for 16 h. Cells were harvested for HMG-CoA 
reductase activity measurements and isolation of poly(A+) RNA. Activity and mRNA levels were determined as outlined under “Methods” 
on pooled triplicate cultures. Quantitation of mRNA was done by cutting bands identified by autoradiography (see Fig. 5) and liquid 
scintillation counting. HMGR, HMG-CoA reductase. 
Condition HMGR 
HMGR GAPDH mRNA ratio 
activity“ mRNA mRNA (HMGR/GAPDH) 
prnol/rnin/mg dPm 
Exp. 1 
Media 668 +- 38 266  229 1.16 (loo)* 
25-Hydroxycholesterol 102 +- 2 145  211 0.69 (59) 
15a-Fluorolanost-7-en-3~-ol 108 +- 8 462 189 2.44 (210) 
Actin 
mRNA  (HMGR/Actin) 
mRNA ratio 
Exp. I1 
Media 856 375 2.28 (100) 
25-Hydroxycholestero1 376  285 1.32 (58) 
15a-Fluorolanost-7-en-3/j”ol 1947  387 5.03 (221) 
Average of triplicate assays f S.D. 
* Numbers in parentheses  are  percent media control value. 
TABLE 111 
Effect of 25-hydroxycholesterol and 15a-fluorolanost-7-en-3fl-ol upon 
HMG-CoA reductase activity, mRNA, synthesis, and degradation in 
treated CHO celk; 
CHO cells were treated with 25-hydroxycholestero1 (25-OH) or 
15a-fluorolanosterol (15a-F). Enzyme activity, mRNA levels, and 
synthesis rates were determined as outlined under “Methods” and 
values are expressed as a percent of control. Enzyme half-life was 
determined as described in Fig. 6.  All values are  means f S.E., with 
the number of independent  experiments given in  parentheses. 
tr( 
% control h 
Sterol Activity Protein  mRNASynthesis Degradation’ 
Control 100 100  100 100 3.1 t- 0.2 (9) 
25-OH 17 f 3 (4) 15 f 5 (3) 25 +- 5 (5) 20 f 4 (2) 1.3 +- 0.3 (3) 
1 5 ~ ~ - F  45 f 5  (7) 46 f 1 (2) 195 f 21 (4) 65 f 5 (4) 3.2 f 0.3 (5) 
either pulse-labeled with [35S]methionine and chased with 
excess unlabeled methionine in the presence or absence of 
sterol  or  pretreated for 16 h with 15a-fluorolanost-7-en-P-01 
and then labeled and chased in  the presence of sterol. Al- 
though pretreatment with sterol reduced the incorporation of 
[36S]methionine into reductase during the  2-h pulse ( t  = 0), 
the 150-fluorolanostenol had no effect on the half-life of the 
enzyme. The average rate of degradation of the newly synthe- 
sized reductase determined  in five separate  experiments was 
not significantly different from that seen in control cells 
(Table 111). It has been suggested that sterol regulation of 
reductase degradation is indirect and mediated by its effects 
on enzyme activity  and mevalonate availability (7, 34). Thus 
the lack of effect of l5a-fluorolanostenol  on HMG-CoA re- 
ductase degradation might be related to  its relative lack of 
potency as  an inhibitor  or reductase (Table 11). To test  this 
possibility, 25-hydroxycholesterol, a potent transcriptional 
regulator of HMG-CoA reductase (Ref. 3 and Fig. 4), was 
added to cells at a  concentration of  250  nM. This resulted in 
a 45% decrease in HMG-CoA reductase activity after  6 h, a 
value similar to  that seen when cells are  treated for 16 h with 
10 p M  15a-fluorolanostenol. Under these conditions, 25-hy- 
droxycholesterol increased the  rate of degradation of HMG- 
CoA reductase 3.5-fold (data  not  shown).  The  inability of 15a- 
fluorolanostenol to accelerate reductase degradation is thus 
not a result of its more moderate inhibition of reductase 
activity. The  data for oxysterol effects on HMG-CoA reduc- 
tase activity, mRNA, synthesis, and degradation are summa- 
rized in  Table 111. These  results suggest that 15a-fluorolan- 
ostenol, in  contrast  to 25-hydroxycholesterol, is a  post-tran- 
scriptional regulator of HMG-CoA reductase which acts solely 
at  the level of translation. 
DISCUSSION 
The results  presented in the  current study characterize the 
metabolic behavior of 15a-fluorolanost-7-en-3~-01, a  synthetic 
analogue of the natural substrate for the lanosterol 14a- 
methyl demethylase enzyme. We have shown that  the  15a- 
fluorolanostenol functions as a substrate for the lanosterol 
14a-methyl demethylase, as well as serves as a good compet- 
itive inhibitor of the enzyme. Our results substantiate and 
extend previous findings that 15-fluoro-substituted lanosten- 
01s block cholesterol biosynthesis from lanosterol (30). By 
virtue of the 15a-fluor0  substitution,  it  has been possible to 
block complete metabolism of this lanosterol analogue to 
demethylated  sterol which results in accumulation of oxygen- 
ated  sterol  under normal metabolic conditions. These findings 
indicate that 15a-fluor0  substitution  in the lanostenol mole- 
cule is  a modest modification which functions only to impede 
metabolic conversion to end product cholesterol, but  not  other 
properties of the lanostenol molecule. Thus, the ability to 
generate  a  stable oxylanosterol analogue through metabolism 
of the 15a-fluorosterol  as described in  this  report provides us 
with another tool to study the mechanism of oxylanosterol 
regulation of cholesterol synthesis  and HMG-CoA reductase 
activity. 
Experiments  in  cultured cells with the 15a-fluorolanostenol 
have demonstrated that  the 15a-fluorolanost-7-en-3P-01 is an 
active suppressor of HMG-CoA reductase activity under con- 
ditions when metabolism to an oxylanosterol analogue is 
permissive. We observe suppression of the HMG-CoA reduc- 
tase activity only in wild-type CHO cells and not in the 
lanosterol 14a-methyl demethylase-deficient mutant, AR45. 
These  results strongly suggest that metabolism of the 15a- 
fluorolanostenol by the lanosterol 14a-methyl demethylase 
enzyme is required for suppressor activity. Additionally, the 
decrease in enzyme activity is accompanied by a decrease 
immunoreactive protein which is consistent with previous 
reports on oxylanosterol regulation of HMG-CoA reductase 
activity (14). 
Mechanistic studies with sterols, and in particular choles- 
terol  and 25-hydroxycholesterol, have shown that sterol-de- 
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FIG. 6. Effects of 15a-fluorolanost-7-en-3~-ol n HMG- 
CoA reductase synthesis and degradation. A and B, CHO  cells 
were labeled with [3sS]methionine for the indicated times in the 
presence of (0) or absence (0) of sterols. Incorporation of [%SI 
methionine  into  total  acid-perceptible proteins and  immunoprecipit- 
able  HMG-CoA  reductase was determined as described  under “Meth- 
ods.” A, acid-precipitable  radioactivity. Data represent the average 
and  standard error of duplicate  determinations on replicate dishes. 
B ,  HMG-CoA reductase. Data represent disintegrations/min eluted 
from gel slices, corrected for nonspecific  radioactivity.  Curves were 
fitted by linear least squares analysis  (Cricket  Graph,  Microsoft) (R2 
> 0.9). C, CHO cells were pulse-labeled for 2 h with [35S]methionine 
and chased in the presence of unlabeled methionine for the indicated 
times. Cells were harvested and radiolabeled HMG-CoA reductase 
was quantitated as described  under  “Methods.”  Curves  were  fitted  by 
exponential least  squares analysis (R2 > 0.97). 0, ethanol  control; 0, 
15oc-fluorolanost-7-en-3~-01 was added at the beginning of the chase; 
W, cells were treated with 15a-fluorolanost-7-en-3~-ol f r 16 h prior 
to the addition of label. 
pendent regulation of HMG-CoA reductase activity and 
expression is due to inhibition of transcription of the reduc- 
tase gene (3). An octanucleotide cis-acting DNA sequence in 
?ductme by Fluorolanostenol 
the 5”flanking region of the reductase gene appears to be 
responsible for sterol-dependent  control of gene transcription 
and  is  thought to be the core binding site for a sterol-binding 
protein which represses transcription (35-37). It has also been 
demonstrated that regulation of reductase activity by sterols 
correlates with the ability of sterols to  interact with a cytosolic 
oxysterol-binding protein (38). Viewed collectively, these  data 
support the conclusion that sterols regulate HMG-CoA re- 
ductase through  transcriptional  control mediated at least in 
part through the action of a common oxysterol binding pro- 
tein. The  data we have presented, however, would indicate 
that this general conclusion regarding sterols may not be 
valid. Our results show that  the 15a-fluorooxylanosterol an- 
alogue generated in situ regulates reductase expression 
through a post-transcriptional process. The decrease in re- 
ductase activity caused by the sterol is not accompanied by a 
decrease in reductase mRNA, but  rather an actual increase. 
Similar  post-transcriptional  control of HMG-CoA reductase 
expression by 24,25-epoxylanosterol has been described (39). 
When metabolism of this compound to  the epoxycholesterol 
was blocked, it no longer inhibited reductase activity in  a  rat 
intestinal epithelial cell line. However, in both  primary rat 
hepatocytes and CHO cells, the oxidolanosterol post-tran- 
scriptionally inhibited reductase synthesis  and  enhanced re- 
ductase degradation even when its demethylation was inhib- 
ited with ketoconazole (39). In  contrast to all other sterols 
examined to date, treatment of CHO cells with the 15a- 
fluorolanostenol has no effect on the degradation rate of 
HMG-CoA reductase. The 15a-fluorooxylanostenol metabo- 
lite thus appears to be unique in the manner of its regulation 
of HMG-CoA reductase, inhibiting translation without af- 
fecting either  transcription  or enzyme degradation. 
The present findings dictate that previous assumptions  and 
data used to support the concept of a non-steroidal regulator 
of HMG-CoA reductase activity be re-evaluated. In  particular, 
the basic premise that all sterols regulate HMG-CoA reduc- 
tase through a 25-hydroxycholestero1 mechanism is shown 
here to be false. Thus,  experiments which employ 25-hydrox- 
ycholesterol to totally account for sterol regulation are subject 
to misinterpretation. For example, when 25-hydroxycholes- 
terol is used in combination with mevalonic acid to regulate 
HMG-CoA reductase activity, the mevalonic acid effect can- 
not be assigned exclusively to a “non-steroidal” regulator. In 
fact, conditions which employ mevalonic acid to generate a 
non-steroidal regulator, either  in mutant cells (6), or in com- 
bination  experiments using 25-hydroxycholesterol plus com- 
pactin  (7), favor synthesis of oxylanosterols (15). Of interest 
in this regard is the report that inhibition of HMG-CoA 
reductase by a 32-carboxylic acid derivative of lanosterol 
(SKF 104976) requires mevalonate (40), whereas inhibition 
by 24(S),25-oxidolanosterol does not  (39). Additionally, Chin 
et al. (41) have shown that sterols can effect HMG-CoA 
reductase expression independently of transcriptional proc- 
esses. Cohen and Griffioen (42) have also differentiated sterol 
metabolites of mevalonate whose effects upon reductase 
mRNA can or cannot be replaced by  exogenous low density 
lipoprotein. Thus,  the designation of the reductase transla- 
tional regulator as  non-steroidal should not be accepted with- 
out  further proof of identity  obtained  through isolation and 
absolute characterization. 
Our approach to understanding the mechanism of regula- 
tion of HMG-CoA reductase by endogenously generated oxy- 
sterols  has focused on the lanosterol  14a-methyl demethyla- 
tion cycle (13, 14, 16). Synthesis, chemical characterization, 
and metabolic studies with the novel substrate/inhibitor,  15a- 
fluorolanost”i-en-3~-ol, described in  this  report,  extend our 
Modulation of HMG-Co Reductase by Fluorolanostenol 22599 
previous findings in this general area. The novel metabolic 
behavior of the 15a-fluorolanostenol demonstrates the possi- 
bility that manipulation of the lanosterol demethylation cycle 
through targeted synthesis can lead to a novel means to 
control HMG-CoA reductase activity and cholesterol biosyn- 
thesis. Our activities are  continuing  in  this area. 
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